cis-Diammine-1,l-cyclobutane dicarboxylate platinum(II) (carboplatin) was developed by Harrap et al. (1980) as a second generation platinum coordination compound. Clinical trials indicated that this analogue is also highly active against several human tumour types (Perry et al., 1986; Beer et al., 1987) . Carboplatin differs from cis-diamminedichloroplatinum(II) (cisplatin) with respect to pharmacological properties such as slower drug elimination due to a different aqueous solubility (Los et al., 199 la) and a lower protein binding capacity (McVie et al., 1985) , as a result of structural changes of cisplatin (Harland et al., 1984; Zwelling, 1987) . The cytotoxicity of platinum compounds is due to reaction of the platinum molecule with nucleophilic sites on the DNA (Meyn et al., 1980; Terheggen et al., 1988) . Carboplatin is similar to cisplatin with regard to the type of DNA lesions, which are presumably responsible for the cytotoxicity (Zwelling et al., 1979; Roberts & Friedlos, 1981; Micetich et al., 1985; Knox et al., 1986; Fichtinger-Schepman et al., 1989; Teicher et al., 1991) .
Hyperthermic enhancement of effects of cisplatin both in vitro (Wallner et al., 1986; Wallner & Li, 1987; Herman et al., 1988) and in vivo (Alberts et al., 1980; Overgaard et al., 1991) has generated considerable interest as a therapy for malignancy. Carboplatin also seems to be a promising agent for combination with hyperthermia. Cohen and Robins (1987) found that carboplatin-induced cytotoxicity was enhanced by heat, in vitro. Ohno et al. (1991) reported that, in rats bearing a fibrosarcoma, the simultaneous combination of carboplatin and whole body hyperthermia produced less toxicity to normal tissues than a similar treatment using cisplatin. The former combination therefore produced an increase in therapeutic gain over that seen with the latter. With respect to timing and sequencing of cisplatin and heat, it is generally accepted that simultaneous drug and heat exposure is most cytotoxic to cultured cells (Wallner et al., 1986; Wallner & Li, 1987) . Similarly, the sequence of heat and carboplatin exposure is also one factor which affects the magnitude of the thermal enhancement (Baba et al., 1989) . However, there is a paucity in information as to how timing and sequence between heat and carboplatin may influence carboplatin-induced cytotoxicity.
We examined the influence of combining heat and cisplatin or carboplatin exposure on survival of HeLa cells. The effects of heat/drug treatment period and the sequence were examined. We have also studied the relationship between carboplatin-mediated cytotoxicity and intracellular platinum concentrations. 265 gM carboplatin, for the same period. To investigate heat/ drug sequencing, the cells were exposed to heat for 30 min at 42.8°C at varying times before, during or after the start of treatment with either cisplatin or carboplatin at concentrations of 33.2 gM or 265 JLM, respectively, for 30 min. These concentrations were equal to the IC50s for 30 min treatment with the drugs as determined in dose response survival experiments ( Figure 1 ). The heat exposure involved placing cells in a glass tube and immersing the tube, tightly sealed with a sterile rubber stopper and punctured with needles for inflow and outflow of air, in a water bath heated to a precise temperature. The temperature of the water bath was automatically maintained at 42.8°C within ± 0.1°C. After drug treatments, the cells were washed three times with fresh, drug-free HBSS heated to the same temperature.
Materials and methods

Drugs
Survival experiments Cell survival assay was carried out using the colony formation method. After heat/drug exposure, the cells were washed three times with HBSS. The number of cells in each group was counted and the cells were plated into 60-mm sterile plastic culture dishes (Corning No. 25010, USA) , in triplicate at two dilutions (300 and 500 cells for control; 1,000 and 3,000 cells for each treatment group) and incubated in a humidified atmosphere with 5.0% CO2 at 37.0°C. After 1 week, the colonies were fixed with ethanol, and stained with Giemsa solution. Colonies of 50 or more cells were counted. Each experiment was repeated three times.
Determination of intracellular platinum concentrations
After treatment with 33.2 JLM of cisplatin or 265 ylM of carboplatin for 30 min, before, during or after 30 min exposure to heat with an interval of 30 min, the cells were placed on ice and washed three times with drug-free HBSS to remove extracellular drug. The cells were then stored in a freezer. The final cell pellet collected was sonicated and the mass of intracellular platinum was determined by atomic absorption spectrophotometry in a pyrocoated graphite cuvette (Hitachi Model 180-7444, Hitachi, Ltd., Tokyo, Japan), using a polarised flameless atomic absorption spectrophotometer (Zeeman Model Z-8000, Hitachi, Ltd., Tokyo, Japan) (Leroy et al., 1977) . Platinum atomic absorption standard solution (No. P-6401, Sigma Co., St. Louis, MO, USA) was diluted to two different concentrations and these were run with each experiment for calibration. The concentration of platinum was expressed as ytg/107 cells.
Statistical analysis The Welch-Aspin t-test was used to determine significance of the difference in slopes of the time-dependent survival curves (Snedecor & Cochran, 1989; Krag et al., 1990) . Comparisons of intracellular platinum concentrations between treatment groups were made using Student's t-test. When the value of P was less than 0.05, the difference was considered to be statistically significant.
Results
Effects of drug alone and drug/heat combination sequencing on HeLa cells The value of plating efficiency for control cells was 92.0 ± 7.8%. All the time-dependent survival response curves showed exponential inhibition of the clonogenic activity of HeLa cells. The slopes of time-heat/drug response curves were calculated for cisplatin and carboplatin. The regression coefficients from our data gave slopes of -0.0430 and -0.1331 min-' for cisplatin alone, and for simultaneous treatment with cisplatin and heat, respectively. Hence, heat produced a 3.10-fold increase in the slope. The corresponding estimates for carboplatin were -0.0154 and -0.0456 min-' .
Heat therefore gave a 2.96-fold increase in the slope, a value similar to that for cisplatin. The concomitant exposure to heat and cisplatin showed a greater inhibition of the surviving fraction than seen in any of the other groups treated with cisplatin, with significant differences in the slopes (P<0.01), as shown in Figure 2 . In case of carboplatin, when exposure to heat was during or prior to carboplatin treatment, the effect on the surviving fraction was greatest, with statistically significant differences in the slopes (P<0.01), as shown in Figure 3 . Table I shows the intracellular platinum concentration of each combination of heat and drugs, compared with cells treated with the drug alone. For cisplatin, a significantly higher platinum concentration was seen in cells exposed to heat and cisplatin simultaneously, compared with cells treated with heat following or prior to cisplatin (P <0.05). In the case of carboplatin, cells treated with heat before the drug had intracellular concentrations of platinum which were 2.75-fold higher than seen in the drug alone treated group (P < 0.01). However, in the case of carboplatin exposure prior to heat treatment, there was a decrease in platinum concentrations to levels lower than seen with the drug alone.
Discussion
Heat exposure markedly enhanced the cytotoxicity induced by either cisplatin or carboplatin, findings comparable to results seen in other studies (Micetich et al., 1985; Cohen & Robins, 1987) . Our results showed that cisplatin cytotoxicity was most enhanced by heat when these treatments were given simultaneously. Several previous studies have also shown that the simultaneous exposure of cisplatin and heat resulted in the (Hahn & Strande, 1976) and hyperthermia induced inhibition of DNA repair (Meyn et al., 1979 adduct formation at elevated temperature was higher than seen at normal temperature (Meyn et al., 1980; Los et al., 1982) . With regard to the first mechanism mentioned above, other investigators have reported that heat increases the intracellular platinum concentration in cells exposed to cisplatin in vitro (Wallner et al., 1986; Los et al., 1991b) and in vivo (Alberts et al., 1980) and our data show that the heatinduced increase in intracellular platinum concentrations correlates with decrease in the survival of HeLa cells. However, the decrease in survival of HeLa cells which we have observed cannot be explained by increased platinum concentrations alone. Firstly, although heat exposure prior to and during carboplatin was equally toxic (Figure 3) , the uptake of carboplatin into cells was higher after heat prior to carboplatin treatment than after simultaneous heat and carboplatin treatment. Simultaneous heat and carboplatin produced a 2.96-fold greater effect on cell survival but only a 1.42-fold increase in intracellular platinum levels (Table I) . On the other hand, the increased effects seen for heat prior to carboplatin were almost identical (2.85 vs 2.75).
Secondly, although the drug given alone and immediately prior to heat exposure were almost equally cytotoxic ( Figures  2 and 3) , platinum levels in cells treated with heat prior to drug exposure were lower than for drug alone (Table I ). The first point may mean that the carboplatin-induced cytotoxicity could be a result of an increased rate of DNA lesion formation during heating. Another possible explanation is that heat increases cell membrane permeability to drugs (Arancia et al., 1989) and the membrane transport of drugs (Hahn et al., 1975) thereby altering cellular metabolism (Hahn & Shiu, 1983) . Based on these reasons, the overall kinetics of carboplatin may change. The second observation above could possibly be explained if heat increases drug excretion before formation of DNA lesions. Micetich et al. (1985) have shown that DNA adduct formation reaches a maximum several hours after cisplatin or carboplatin exposure. Although the time course for carboplatin is thought to be different from that for cisplatin (Micetich et al., 1985; Knox et al., 1986; Los et al., 19991b) , the relatively short intervals which we used in our study did not show any difference in effects between carboplatin before heat treatment and cisplatin before heat treatment.
Various side effects result from combined use of heat and anticancer drugs in a clinical setting, including increased nephrotoxicity by cisplatin (Gonzales-Vitale et al., 1977; Campbell et al., 1983) and myelosuppression by carboplatin (Curt et al., 1983; Stemnberg et al., 1985) . However, optimal use of heat/drug scheduling shows promise for combination treatment of cancer patients, as reported by Baba et al. (1989) . Our findings may be helpful in the design of combined treatments with hyperthermia and cisplatin analogues.
